Treatment discontinuation due to adverse events as an overall measure of tolerance and safety of jak-inhibitors: an international collaboration of registries of rheumatoid arthritis patients (the “JAKPOT” study)
14/08/2023
E. Nham1 , R. Aymon1 , D. Mongin1 , S. A. Bergstra2 , D. Choquette3 , C. Codreanu4 , O. Elkayam5 , K. Hyrich6,7, F. Iannone8 , N. Inanc9 , L. KearsleyFleet6 , E. Kristianslund10, T. K. Kvien10, B. Leeb11,12, G. Lukina13, D. Nordström14, K. Pavelka15, M. Pombo-Suarez16, Z. Rotar17, M. J. Santos18, D. Courvoisier1 , K. Lauper1,6, A. Finckh1
EULAR 2022
DOI: 10.1136/annrheumdis-2022-eular.2342
https://ard.bmj.com/content/81/Suppl_1/177